Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.

Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.